Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes

NCT00359879 · Completed

Last updated 2026-05-28

This clinical trial compared the effects of taking exenatide before lunch and dinner versus before breakfast and dinner in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 377 people

Who can join Ages 18–75 · all sexes

Timeline Started 2006-09 · est. completion 2007-07

Where 15 sites · Brazil, Mexico

What this study is testing ClinicalTrials.gov NCT00359879 ↗

Description as written by the study sponsor.

This trial is designed to compare the effects of twice-daily (before lunch and before dinner) exenatide plus oral antidiabetic (OAD) agents and twice-daily (before breakfast and before dinner) exenatide plus OAD with respect to glycemic control (HbA1c) in patients with type 2 diabetes.

Treatments tested

exenatide also known as Byetta Drug

subcutaneous injection, 5mcg or 10mcg, twice a day (before lunch and dinner)
exenatide also known as Byetta Drug

subcutaneous injection, 5mcg or 10mcg, twice a day (before breakfast and dinner)

Main thing measured	Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 12
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00359879 ↗